Picture of Xvivo Perfusion AB logo

XVIVO — Xvivo Perfusion AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Brief: Xvivo Perfusion Q2 EBITDA ex-items up at SEK 6.9 million

July 15 (Reuters) - Xvivo Perfusion AB  XVIVO.ST : 
    * Q2 net sales 34.5 million Swedish crowns ($4.1 million) versus 29.1 million crowns year 
ago 
    * Q2 EBITDA ex-items 6.9 million crowns versus 4.6 million crowns year ago 
    * Says focus during 2016 is therefore to establish STEEN Solution method as the standard 
treatment for lung transplantation  
    * Since acquisition of Vivoline company will intensify research and development in cardiac 
transplantation  
 
     
Source text for Eikon:  ID:nWkrgn7235  
     
Further company coverage:  XVIVO.ST  
 
($1 = 8.4907 Swedish crowns) 
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))

Recent news on Xvivo Perfusion AB

See all news